Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025


Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET.

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit awards to 20 new non-executive employees.

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025


will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025


Crinetics will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL.

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.